<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"
                      "http://www.w3.org/TR/REC-html40/loose.dtd">
<HTML>
<HEAD>
<TITLE>extropians: Re: Protein antifreeze</TITLE>
<META NAME="Author" CONTENT="Jeff Davis (jdavis@socketscience.com)">
<META NAME="Subject" CONTENT="Re: Protein antifreeze">
</HEAD>
<BODY BGCOLOR="#FFFFFF" TEXT="#000000">
<H1>Re: Protein antifreeze</H1>
<!-- received="Sat Jan 15 18:52:17 2000" -->
<!-- isoreceived="20000116015217" -->
<!-- sent="Sat, 15 Jan 2000 17:48:41 -0800" -->
<!-- isosent="20000116014841" -->
<!-- name="Jeff Davis" -->
<!-- email="jdavis@socketscience.com" -->
<!-- subject="Re: Protein antifreeze" -->
<!-- id="3.0.6.32.20000115174841.007b9b90@coastside.net" -->
<!-- inreplyto="Protein antifreeze" -->
<STRONG>From:</STRONG> Jeff Davis (<A HREF="mailto:jdavis@socketscience.com?Subject=Re:%20Protein%20antifreeze&In-Reply-To=&lt;3.0.6.32.20000115174841.007b9b90@coastside.net&gt;"><EM>jdavis@socketscience.com</EM></A>)<BR>
<STRONG>Date:</STRONG> Sat Jan 15 2000 - 18:48:41 MST
<P>
<!-- next="start" -->
<UL>
<LI><STRONG>Next message:</STRONG> <A HREF="0783.html">Eliezer S. Yudkowsky: "Re: BBC Polemics: Help needed!"</A>
<LI><STRONG>Previous message:</STRONG> <A HREF="0781.html">upgrade: "Re: [SCAM] This is getting to be too much..."</A>
<!-- nextthread="start" -->
<LI><STRONG>Next in thread:</STRONG> <A HREF="0786.html">Doug Jones: "Re: Protein antifreeze"</A>
<LI><STRONG>Reply:</STRONG> <A HREF="0786.html">Doug Jones: "Re: Protein antifreeze"</A>
<LI><STRONG>Maybe reply:</STRONG> <A HREF="0797.html">CurtAdams@aol.com: "Re: Protein antifreeze"</A>
<LI><STRONG>Maybe reply:</STRONG> <A HREF="0874.html">Jeff Davis: "Re: Protein antifreeze"</A>
<!-- reply="end" -->
<LI><STRONG>Messages sorted by:</STRONG> 
<A HREF="date.html#782">[ date ]</A>
<A HREF="index.html#782">[ thread ]</A>
<A HREF="subject.html#782">[ subject ]</A>
<A HREF="author.html#782">[ author ]</A>
</UL>
<HR NOSHADE><P>
<!-- body="start" -->
<P>
Friends,
<BR>
<P>This thread, recently initiated by John Clark, and then splendidly
<BR>
elaborated by
<BR>
Anders, Robert B, and Gene Leitl, proposed using genetically engineered
<BR>
bacteria in a cryonic suspension protocol to effect the intra-cellular
<BR>
production of cryoprotectant.
<BR>
<P>Re that discussion, I recently found the following at Eurekalert, under the
<BR>
title:  AstraZeneca executes option agreement for Vion-Epttco cancer
<BR>
therapy technology.
<BR>
<P><P><EM>&gt;TAPET® (Tumor Amplified Protein Expression Therapy), Vion's core platform
</EM><BR>
<EM>&gt;    technology, are highly attenuated bacteria that, in preclinical
</EM><BR>
studies, have
<BR>
<EM>&gt;    demonstrated preferential replication in tumors compared to normal
</EM><BR>
tissues. The
<BR>
<EM>&gt;    bioengineered bacteria have demonstrated an excellent safety profile
</EM><BR>
in preclinical
<BR>
<EM>&gt;    toxicology studies. Preferential replication allows the bacteria to
</EM><BR>
produce and deliver
<BR>
<EM>&gt;    a variety of anti-cancer therapeutic products at high concentrations
</EM><BR>
to tumors while
<BR>
<EM>&gt;    minimizing toxicity to normal tissues. By bringing the &quot;drug factory&quot;
</EM><BR>
preferentially to
<BR>
<EM>&gt;    the tumor, Vion believes that TAPET may result in a cancer therapy
</EM><BR>
that is more
<BR>
<EM>&gt;    concentrated, more effective and less toxic to normal tissue.
</EM><BR>
<P>Find more details at: 
<BR>
<P><A HREF="http://www.eurekalert.org/">http://www.eurekalert.org/</A>
<BR>
<P><P><P>-------------------------------------------------------------------
<BR>
<P>A related little note:
<BR>
<P>I don't own any stock, being--as I call it --&quot;independently austere&quot;.  But
<BR>
back in December, while looking over a friend's shoulder--he was checking
<BR>
on his stocks--I suggested he look up Alexion Pharmaceuticals.  They'd been
<BR>
doing stem cell research as well as spinal cord injury repair work.
<BR>
Alexion (ALXN) was at 18.  Yesterday, with another friend all agog over the
<BR>
bull market, I checked Alexion again.  It was at 34.  Hmmmm.
<BR>
<P>I think I'll keep an eye on Vion Parmaceuticals, Inc. (NASDAQ NM: VION).
<BR>
As of today it is at $ 8.5625
<BR>
<P>Anyone care to track a portfolio based on Eurekalert announcements?
<BR>
<P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Best, Jeff Davis
<BR>
<P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&quot;Everything's hard till you know how to do it.&quot;
<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ray Charles				
<BR>
<P><!-- body="end" -->
<HR NOSHADE>
<UL>
<!-- next="start" -->
<LI><STRONG>Next message:</STRONG> <A HREF="0783.html">Eliezer S. Yudkowsky: "Re: BBC Polemics: Help needed!"</A>
<LI><STRONG>Previous message:</STRONG> <A HREF="0781.html">upgrade: "Re: [SCAM] This is getting to be too much..."</A>
<!-- nextthread="start" -->
<LI><STRONG>Next in thread:</STRONG> <A HREF="0786.html">Doug Jones: "Re: Protein antifreeze"</A>
<LI><STRONG>Reply:</STRONG> <A HREF="0786.html">Doug Jones: "Re: Protein antifreeze"</A>
<LI><STRONG>Maybe reply:</STRONG> <A HREF="0797.html">CurtAdams@aol.com: "Re: Protein antifreeze"</A>
<LI><STRONG>Maybe reply:</STRONG> <A HREF="0874.html">Jeff Davis: "Re: Protein antifreeze"</A>
<!-- reply="end" -->
<LI><STRONG>Messages sorted by:</STRONG> 
<A HREF="date.html#782">[ date ]</A>
<A HREF="index.html#782">[ thread ]</A>
<A HREF="subject.html#782">[ subject ]</A>
<A HREF="author.html#782">[ author ]</A>
</UL>
<!-- trailer="footer" -->
<HR NOSHADE>
<P>
<SMALL>
<EM>
This archive was generated by <A HREF="http://www.hypermail.org/">hypermail 2b29</A> 
: <EM>Thu Jul 27 2000 - 14:02:18 MDT</EM>
</EM>
</SMALL>
</BODY>
</HTML>
